NASPGHAN Urges ACIP to Maintain the Universal Hepatitis B Birth-Dose Recommendation
The universal hepatitis B birth-dose vaccination remains a critical, evidence-based public health measure that protects newborns from hepatitis B virus (HBV) infection and its long-term consequences. Maintaining this recommendation is essential to ensuring consistent, equitable protection for all infants across the United States.
NASPGHAN has submitted formal comments to the ACIP strongly urging the committee to preserve the existing universal birth-dose policy. Decades of research and real-world experience demonstrate that early immunization is both safe and highly effective in reducing perinatal and childhood HBV transmission.
NASPGHAN continues to support vaccine policies that prioritize prevention, equity, and the long-term health of children.
